People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allovir, Inc. | — | Biotechnology | Series D+ | $151.3M | $5.0B | 2018 |
| iTeos Therapeutics, Inc. | — | Pharma | Series D+ | $125.4M | $4.4B | 2020 |
David Hallal at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Hallal on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ansbert Gadicke | 2 | 7 |
| John Wilson | 1 | 11 |
| Detlev Biniszkiewicz | 1 | 4 |
| Chris Buyse | 1 | 2 |
| Juan Vera | 1 | 2 |
| Vikas Sinha | 1 | 1 |
| Morana Jovan-Embiricos | 1 | 1 |
| Malcom Brenner | 1 | 1 |
| Michel Detheux | 1 | 1 |
| Priyanka Belawat | 1 | 1 |
| Tim Van Hauwermeiren | 1 | 1 |
| Jonathan Skipper | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.